Proton Pump Inhibitors (PPIs)

Proton Pump Inhibitors (PPIs)


Global Proton Pump Inhibitors (PPIs) Market to Reach US$3.6 Billion by 2030

The global market for Proton Pump Inhibitors (PPIs) estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Over the Counter PPIs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Prescription PPIs segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$798.3 Million While China is Forecast to Grow at 6.2% CAGR

The Proton Pump Inhibitors (PPIs) market in the U.S. is estimated at US$798.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$749.0 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Proton Pump Inhibitors (PPIs) Market - Key Trends and Drivers Summarized

How Are Proton Pump Inhibitors (PPIs) Revolutionizing the Treatment of Acid-Related Disorders?

Proton Pump Inhibitors (PPIs) are revolutionizing the treatment of acid-related disorders by providing a highly effective means of reducing stomach acid production, thereby alleviating symptoms and promoting healing in conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. PPIs work by irreversibly inhibiting the hydrogen-potassium ATPase enzyme in the stomach lining, which is responsible for acid secretion. This mechanism allows for a more sustained and significant reduction in acid levels compared to other treatments like antacids or H2 receptor antagonists. As a result, PPIs have become the cornerstone therapy for managing chronic acid-related conditions, offering relief from symptoms such as heartburn, regurgitation, and discomfort. The effectiveness of PPIs in both symptom control and the healing of erosive esophagitis and peptic ulcers has made them one of the most commonly prescribed medications worldwide, significantly improving the quality of life for millions of patients.

What Innovations Are Enhancing the Functionality of Proton Pump Inhibitors?

Innovations in proton pump inhibitors (PPIs) are enhancing their functionality through the development of new formulations, improved drug delivery systems, and combination therapies. Recent advancements include the creation of delayed-release and extended-release formulations that allow for more consistent acid suppression over a 24-hour period, improving patient adherence and outcomes. Additionally, researchers are exploring novel drug delivery methods, such as orally disintegrating tablets (ODTs) and liquid suspensions, which offer convenience and improved absorption, particularly for patients who have difficulty swallowing pills. Another significant innovation is the development of combination therapies that pair PPIs with other medications, such as prokinetics or antibiotics, to address a broader range of gastrointestinal conditions, including those caused by Helicobacter pylori infections. These combination therapies enhance the effectiveness of treatment and provide a more comprehensive approach to managing acid-related disorders. These innovations are making PPIs more versatile, accessible, and effective, ensuring that a wider range of patients can benefit from their use.

How Do Proton Pump Inhibitors Impact Long-Term Patient Outcomes and Healthcare Costs?

Proton Pump Inhibitors (PPIs) have a profound impact on long-term patient outcomes by providing sustained relief from chronic acid-related conditions and preventing complications such as esophageal strictures, Barrett`s esophagus, and gastrointestinal bleeding. By effectively managing symptoms and promoting mucosal healing, PPIs help patients maintain a better quality of life and reduce the risk of serious complications that can arise from untreated acid disorders. However, the long-term use of PPIs has raised concerns about potential side effects, such as nutrient malabsorption, increased risk of bone fractures, and susceptibility to certain infections. Despite these concerns, when used appropriately under medical supervision, the benefits of PPIs in controlling acid production and preventing complications far outweigh the risks for most patients. From a healthcare cost perspective, PPIs are generally cost-effective due to their ability to prevent hospitalizations and more invasive treatments associated with complications of acid-related disorders. The widespread availability of generic PPI formulations also makes these medications more affordable, further reducing the financial burden on both patients and healthcare systems.

What Trends Are Driving Growth in the Proton Pump Inhibitors Market?

Several trends are driving growth in the Proton Pump Inhibitors (PPIs) market, including the rising prevalence of gastrointestinal disorders, increasing awareness of acid-related conditions, and the continued demand for over-the-counter (OTC) treatment options. As lifestyles change and diets become more processed, there is a growing incidence of conditions like GERD, peptic ulcers, and dyspepsia, leading to greater demand for effective acid suppression therapies. Additionally, increased awareness of acid-related disorders and their potential complications is prompting more individuals to seek medical treatment, driving the prescription and OTC markets for PPIs. The availability of OTC PPIs has expanded access to these medications, allowing individuals to manage symptoms without the need for a prescription, which is particularly appealing to those with mild or occasional symptoms. Furthermore, ongoing research into the long-term safety and efficacy of PPIs is likely to lead to the development of newer, more targeted formulations that cater to specific patient populations, such as those with complex or refractory conditions. These trends underscore the essential role of PPIs in modern gastroenterology and their continued relevance in managing acid-related disorders in the global population.

Select Competitors (Total 37 Featured) -
  • AstraZeneca plc
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories
  • Drugwatch.com, LLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Janssen Global Services, LLC
  • Johnson & Johnson Services, Inc.
  • LUPIN Limited
  • Perrigo Company PLC
  • Pfizer Limited
  • RedHill Biopharma Ltd.
  • Sun Pharmaceutical Industries Ltd.;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Proton Pump Inhibitors (PPIs) – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Gastrointestinal Disorders Driving Demand for PPIs
Growing Awareness of Acid Reflux and GERD Management Options
Rising Geriatric Population and Associated Gastrointestinal Conditions
Concerns Over Long-Term PPI Use and Potential Side Effects Influencing Prescribing Practices
Generic Drug Market Expansion Following PPI Patent Expirations
E-commerce and Online Pharmacies Expanding PPI Availability
Challenges in Over-the-Counter PPI Sales and Self-Medication Risks
Impact of Digital Health Technologies on Patient Management and Monitoring
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Proton Pump Inhibitors (PPIs) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Over the Counter PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Over the Counter PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Over the Counter PPIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Prescription PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Prescription PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Prescription PPIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
JAPAN
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Japan Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Japan 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
CHINA
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 35: China Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: China Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: China 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
EUROPE
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 41: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
FRANCE
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 50: France Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: France Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: France 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 53: France Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
GERMANY
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Germany Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Germany 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 59: Germany Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Italy Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Italy 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 65: Italy Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
UNITED KINGDOM
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: UK Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: UK 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 71: UK Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
SPAIN
TABLE 74: Spain Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Spain Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Spain 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 77: Spain Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Spain Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Spain 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
RUSSIA
TABLE 80: Russia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Russia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Russia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 83: Russia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Russia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Russia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Europe Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
AUSTRALIA
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 101: Australia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Australia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Australia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 104: Australia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Australia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Australia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
INDIA
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 107: India Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: India Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: India 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 110: India Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: India Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: India 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 113: South Korea Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: South Korea Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: South Korea 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 116: South Korea Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: South Korea Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: South Korea 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Rest of Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
LATIN AMERICA
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 125: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 126: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 128: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 131: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 134: Argentina Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Argentina Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Argentina 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 137: Argentina Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Argentina Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Argentina 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
BRAZIL
TABLE 140: Brazil Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Brazil Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Brazil 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 143: Brazil Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Brazil Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Brazil 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
MEXICO
TABLE 146: Mexico Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Mexico Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Mexico 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 149: Mexico Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Mexico Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Mexico 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Rest of Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Rest of Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
MIDDLE EAST
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 158: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 159: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 161: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 164: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
IRAN
TABLE 167: Iran Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Iran Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Iran 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 170: Iran Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Iran Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Iran 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
ISRAEL
TABLE 173: Israel Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Israel Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Israel 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 176: Israel Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Israel Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Israel 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Saudi Arabia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Saudi Arabia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Saudi Arabia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Saudi Arabia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 185: UAE Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: UAE Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: UAE 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 188: UAE Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: UAE Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: UAE 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Rest of Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Rest of Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
AFRICA
Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 197: Africa Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Africa Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Africa 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
TABLE 200: Africa Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Africa Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Africa 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings